High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma
Multiple Myeloma
About this trial
This is an interventional treatment trial for Multiple Myeloma
Eligibility Criteria
INCLUSION CRITERIA Stage II to III multiple myeloma, or progression after initial treatment of Stage I disease; early or relapsed Age 18 to 75 years. Pathology reviewed and the diagnosis confirmed at Stanford University Medical Center. Patients with amyloidosis may be eligible for this trial, with approval by the Principle Investigator. Patients must have a Karnofsky performance status > 70%. Aspartate aminotransferase (AST) must be < 2 x upper limit of normal (ULN) Alanine aminotransferase (ALT) must be < 2 x ULN Total bilirubin < 2 mg/dL. Serum creatinine < 2.0 or 24-hour creatinine clearance โฅ 60 mL/min. Patients must be HIV-negative. Patients must provide signed, informed consent. EXCLUSION CRITERIA Severe psychological or medical illness Prior autologous hematopoietic cell transplantation Pregnant Lactating women Smoldering multiple myeloma, Monoclonal gammopathy of unknown significance or primary amyloidosis will be excluded from this study
Sites / Locations
- Stanford University School of Medicine
Arms of the Study
Arm 1
Experimental
High-Dose Sequential Therapy
Cyclophosphamide + Etoposide + Melphalan + Carmustine with Filgrastim